Some neck or back injuries that damage the spinal cord can leave a person partially or completely paralyzed.
Now, for the first time, doctors at ASAN Medical Center have confirmed the efficacy of directly injecting a patient’s own autologous stem cells into the injured spinal cord.
After a severe nerve injury to his neck from a car accident in 1998, a patient named Mr. Park, from Chuncheon, was diagnosed with quadriplegia, or complete paralysis.
After being bedridden for eight years, he began receiving stem cell therapy in 2006. Gradually, he started to regain strength in his arms, and finally was able
Spinal cord injuries, resulting in permanent disability or paralysis in most cases, account for around eleven thousand new cases in the US, annually. Due to the lack of effective treatment strategies, it is considered as the most devastating of all traumatic conditions. Now, a recent study published in the journal Stem Cells reports that activation of ependymal stem/progenitor cells from injured spinal cord (epSPCi), using endogenous stem cell-associated mechanisms, may aid in rescuing neurological function, thereby reversing paralysis associated with spinal cord injuries.
Aileen Anderson and Brian Cummings led the pre-clinical studies for the neural stem cell treatment
A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine’s Sue & Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world’s first clinical trial using human neural stem cells to treat spinal cord injury.
Swissmedic, the Swiss regulatory agency for therapeutic products, has authorized a Phase I/II clinical trial for chronic spinal cord injury, cases in which inflammation has stabilized and recovery has reached a
Hans Keirstead, a researcher at University of California, Irvine, is set to begin a small human trial of his embryonic stem cell treatment on patients with spinal cord injuries. The treatment is designed for patients within 14 days of suffering spinal cord injuries. In rat trials, paralyzed rats were injected with a stem cell formula. The paralyzed rats were able to walk six weeks later.
StemCells Inc announced that interim six-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines. The third patient remains stable.
The data was presented by Armin Curt, M.D., principal investigator for the clinical trial, at the 51st Annual Scientific Meeting of the International Spinal Cord Society in London, England. The trial represents the first